from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2sCRnh2 on July 3, 2017 at 05:37AM
Jury selection in Martin Shkreli’s securities fraud trial have made one thing clear: He’s seemingly become the face of high drug prices.
In an analysis piece, Washington Post Reporter Carolyn Johnson writes potential jurors seemed to have difficulty seeing past Shkreli’s decision to increase the price of Daraprim from $13.50 to $750 per pill.
“The only thing I would be impartial about his which prison he goes to,” one potential juror said.
Johnson said her colleague, Renae Merle, reported more than 250 potential jurors were dismissed through the course of jury selection.
Because of the increase focus on drug prices, pharmaceutical companies have also attempted to dispel the broad stroke of the brush. Johnson writes some companies have pinned Shkreli as one of many outliers in the industry, and have been working to “convince the public that true pharmaceutical companies act more responsibly.